Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents?

ABSTRACT: Non-human primate (NHP)-derived adenoviruses have formed a valuable alternative for the use of human adenoviruses in vaccine development and gene therapy strategies by virtue of the low seroprevalence of neutralizing immunity in the human population. The more recent use of several human adenoviruses as oncolytic agents has exhibited excellent safety profiles and firm evidence of clinical efficacy. This proffers the question whether NHP-derived adenoviruses could also be employed for viral oncolysis in human patients. While vaccine vectors are conventionally made as replication-defective vectors, in oncolytic applications replication-competent viruses are used. The data on NHP-derived adenoviral vectors obtained from vaccination studies can only partially support the suitability of NHP-deri

SUBMITTER: Bots STF 

PROVIDER: S-EPMC7404033 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature